Volrustomig

Multispecific antibody

Also known as MEDI5752

Negativelead readout

Evidence outlook · lead readout

eVOLVE-Lung02 (NCT05984277) · Metastatic Non-small Cell Lung Cancer

The lead readout missed its primary endpoint. The grade and rationale below record what the trial was designed to show and what it found.

eVOLVE-Lung02 (NCT05984277): eVOLVE-Lung02 was a randomized, open-label Phase 3 in 895 participants with metastatic non-small cell lung cancer with progression-free and overall survival as dual primary endpoints. An independent committee judged at an interim review that neither endpoint was likely to be met, and the sponsor stopped the trial. A randomized but open-label trial with a negative result is moderate evidence of no benefit.

Also in development:Cervical Cancer · Phase 3Head and Neck Squamous Cell Carcinoma · Phase 3

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (4)
Cervical Cancer
Head and Neck Squamous Cell Carcinoma
Non-Small Cell Lung Cancer
Other / comorbidity
NCT06097728 · AstraZeneca
2023-11-09 – 2028-11-16 · Unresectable Pleural Mesothelioma
What this study did
Phase 2 (12)
Cervical Cancer
NCT06943833 · AstraZeneca
2025-03-31 – 2029-03-13 · Locally Advanced Cervical Cancer
What this study did
Head and Neck Squamous Cell Carcinoma
NCT07065630 · University of Chicago
2025-10-07 – 2029-08-13 · Head and Neck Cancer, HPV
What this study did
NCT06535607 · AstraZeneca
2024-08-22 – 2028-11-30 · Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 5 Unresectable Pleural Mesothelioma (Volrustomig Monotherapy)
What this study did
Non-Small Cell Lung Cancer
NCT05061550 · AstraZeneca
2022-04-14 – 2030-05-28 · Non-small Cell Lung Cancer
What this study did
NCT06448754 · AstraZeneca
2024-08-27 – 2027-07-30 · Non-small Cell Lung Cancer
What this study did
Other / comorbidity
NCT05702229 · AstraZeneca
2023-01-16 – 2029-05-31 · Gastric Cancer
What this study did
NCT06792695 · AstraZeneca
2025-03-12 – 2028-09-29 · Metastatic Colorectal Cancer
What this study did
NCT05888857 · Institut Bergonié
2025-09 – 2028-09 · Advanced Solid Tumor
What this study did
NCT03741426 · CCTU- Cancer Theme
2020-07-27 – 2027-12-30 · Renal Cell Cancer
What this study did
NCT05775159 · AstraZeneca
2023-04-24 – 2027-10-28 · Hepatocellular Carcinoma, Biliary Tract Cancer
What this study did
NCT05489211 · AstraZeneca
2022-09-06 – 2027-10-01 · Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Urothelial Cancer, Biliary Tract Cancer
What this study did
NCT04379596 · AstraZeneca
2020-06-03 – 2027-05-04 · Gastric Cancer
What this study did
Phase 1 (10)
Head and Neck Squamous Cell Carcinoma
NCT06366451 · Presage Biosciences
2024-05-22 – 2026-03-25 · Head and Neck Squamous Cell Carcinoma
What this study did
Non-Small Cell Lung Cancer
NCT04686305 · AstraZeneca
2021-03-09 – 2027-06-30 · Locally Advanced or Metastatic Non-Small Cell Lung Cancer
What this study did
NCT04612751 · AstraZeneca
2021-02-02 – 2027-05-04 · Advanced or Metastatic NSCLC
What this study did
NCT03819465 · AstraZeneca
2018-12-27 – 2026-07-01 · Metastatic Non-Small Cell Lung Cancer (NSCLC)
What this study did
Other / comorbidity
NCT04541108 · Presage Biosciences
2021-07-26 – 2031-12 · Solid Tumor
What this study did
NCT03530397 · MedImmune LLC
2018-04-24 – 2027-11-30 · Selected Advanced Solid Tumors
What this study did
NCT07000149 · AstraZeneca
2025-07-28 – 2027-01-29 · Advanced Clear Cell Renal Cell Carcinoma
What this study did
NCT05821231 · Institut Claudius Regaud
2023-12-12 – 2026-09-07 · Soft Tissue Sarcoma
What this study did
NCT04522323 · MedImmune LLC
2020-08-05 – 2025-09-26 · Advanced Renal Cell Carcinoma
What this study did
NCT05685472 · AstraZeneca
2022-12-08 – 2025-07-29 · Advanced Solid Tumors
What this study did

Competitive landscape

4 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Cervical Cancer: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Volrustomig: this drugPhase 3Multispecific antibodyPD-1 x CTLA-4not yet gradedNo reviewed efficacy summary in this indication
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor Inhibitornot yet gradedNo reviewed efficacy summary in this indication
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Reliable signalNo reviewed efficacy summary in this indication
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Tisotumab Vedotin Humax-Tf-Adc (Tivdak)ApprovedAntibody–drug conjugateTissue Factor (TF)Partial signal
NCT04697628: Overall Survival (From randomization to date of death due to any cause or censoring date, whichever occurred first (maximum up to 25 months)): Tisotumab Vedotin 11.5 Months (95% CI 9.8 to 14.9) | Chemotherapy 9.5 Months (95% CI 7.9 to 10.7)
NCT03438396: Percentage of Participants With Confirmed Objective Response (OR) as Assessed by the Independent Review Committee (IRC) (From Day 1 through IRC verified disease progression, initiation of new anticancer therapy, study withdrawal, or death, whichever occurred first (approximately 20 months)): Tisotumab Vedotin 23.8 Percentage of Participants (95% CI 15.9 to 33.3)
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
CadonilimabPhase 3Multispecific antibodyPD-1×CTLA-4not yet gradedNo reviewed efficacy summary in this indication
EnlonstobartPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
FamitinibPhase 3Small moleculec-Kit, VEGFR2 (KDR), PDGFRbeta, VEGFR3, FLT1, FLT3not yet gradedNo reviewed efficacy summary in this indication
Notiretatug RezetecanPhase 3Antibody–drug conjugateNectin-4not yet gradedNo reviewed efficacy summary in this indication
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2not yet gradedNo reviewed efficacy summary in this indication
Sutantatug EnvedotinPhase 3Antibody–drug conjugateNectin-4not yet gradedNo reviewed efficacy summary in this indication
CamrelizumabPhase 2/3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
BalstilimabPhase 2Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Lorigerlimab
Phase 2(overall)
Multispecific antibodyPD-1 x CTLA-4
not yet graded(overall)
No reviewed efficacy summary in this indication
ALE.P02
Phase 1/2(overall)
Antibody–drug conjugateClaudin-1 (CLDN1)not yet gradedNo reviewed efficacy summary in this indication
GI-101APhase 1/2Protein / enzyme therapeuticCTLA-4 / IL-2Rβγnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(16 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Volrustomig to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (9)
January 2027 (1)
Phase 1Advanced Clear Cell Renal Cell CarcinomaActive not recruiting
Est. primary completion 2027-01-29 · NCT07000149 · CT.gov ↗
What to watch
May 2027 (1)
Phase 2Gastric CancerActive not recruiting
Est. primary completion 2027-05-04 · NCT04379596 · CT.gov ↗
What to watch
June 2027 (2)
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-06-30 · NCT04686305 · CT.gov ↗
What to watch
Phase 2Metastatic Colorectal CancerActive not recruiting
Est. primary completion 2027-06-30 · NCT06792695 · CT.gov ↗
What to watch
July 2027 (1)
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-07-30 · NCT06448754 · CT.gov ↗
What to watch
October 2027 (1)
Phase 2Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Urothelial Cancer …Recruiting
Est. primary completion 2027-10-01 · NCT05489211 · CT.gov ↗
What to watch
November 2027 (2)
Phase 3Cervical CancerRecruiting
Est. primary completion 2027-11-26 · NCT06079671 · CT.gov ↗
What to watch
Phase 2Gastric CancerRecruiting
Est. primary completion 2027-11-30 · NCT05702229 · CT.gov ↗
What to watch
December 2027 (1)
Phase 2Renal Cell CancerRecruiting
Est. primary completion 2027-12-30 · NCT03741426 · CT.gov ↗
What to watch
2028 (3)
March 2028 (1)
Phase 2Cervical CancerActive not recruiting
Est. primary completion 2028-03-13 · NCT06943833 · CT.gov ↗
What to watch
November 2028 (2)
Phase 3Unresectable Pleural MesotheliomaActive not recruiting
Est. primary completion 2028-11-16 · NCT06097728 · CT.gov ↗
What to watch
Phase 2Cervical CancerRecruiting
Est. primary completion 2028-11-30 · NCT06535607 · CT.gov ↗
What to watch
2029 (1)
August 2029 (1)
Phase 2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2029-08-13 · NCT07065630 · CT.gov ↗
What to watch
2030 (2)
April 2030 (1)
Phase 3Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2030-04-17 · NCT06129864 · CT.gov ↗
What to watch
May 2030 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-05-28 · NCT05061550 · CT.gov ↗
What to watch
2031 (1)
December 2031 (1)
Phase 1Solid TumorActive not recruiting
Est. primary completion 2031-12 · NCT04541108 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

17 August 2026Topline resulteVOLVE-Lung02 Phase III (NCT05984277) discontinued after IDMC futility review
AstraZeneca · Source ↗